ABL Ascend Advanced Therapies Names Suman Subramanian as Chief Business Officer
10.8.2026 10:00:00 CEST | ACCESS Newswire | Press release
ROCKVILLE, MD / ACCESS Newswire / August 10, 2026 / ABL Inc and Ascend Advanced Therapies today announced the appointment of Suman Subramanian as Chief Business Officer (CBO), further strengthening the Company's commercial leadership and its commitment to supporting customers with the development and manufacturing of viral vectors, vaccines, biologics and advanced therapies.
Suman brings nearly two decades of experience and leadership, supporting emerging biotech and large pharma within the biopharmaceutical industry. He will be responsible for leading the company's global commercial organization, including business development, marketing and strategic partnership functions.
As the industry continues to evolve, customers are now increasingly seeking end-to-end CDMO partners capable of translating science and delivering impeccable service whilst reducing technical, operational and manufacturing risks. Through his experience with programs ranging from early-stage development to commercialization, Suman's client-forward and partnership approach guides customers in navigating this increasingly complex path of drug development.
"Our industry and customer expectations are continuously evolving. Scientific know-how still sits at our core, but success today is increasingly dependent on designing products and processes that are manufacturable, scalable and viable from the start-on. Our customers look for partners with comprehensive capabilities which can translate science into a single product development plan. Over the past year, we have strengthened and augmented our leadership team with world-class talent to push the limits of customer experience. Suman's appointment, with his customer-centric mindset and focus on building long-term strategic partnerships, represents another milestone in that journey," said Alessandra Rispoli, Chief Executive Officer of ABL Ascend Advanced Therapies.
Prior to joining ABL Ascend, Suman held executive leadership roles at Stevanato Group, Catalent Cell & Gene Therapy, and West Pharmaceutical Services, where he drove commercial strategy, business transformation, and integrated customer solutions. He has a proven track record of driving business growth, building high-performing organizations, and translating complex scientific capabilities into differentiated customer solutions that create long-lasting value.
"I am excited to join ABL Ascend at such an important time for the company's growth. What attracted me to ABL Ascend is the team's unified vision to seize the opportunity and build one of the industry's most differentiated CDMOs - not only through scientific excellence and manufacturing expertise, but by redefining the customer experience. Our goal is to make ABL Ascend the easiest partner to do business with, creating long-term relationships built on trust, collaboration, agility, and flawless execution. ABL Ascend combines deep scientific leadership, manufacturing excellence and decades supporting biotech, pharma and the U.S. Government. That's something special," said Suman Subramanian.
About ABL Ascend Advanced Therapies
ABL Ascend Advanced Therapies is a global contract development and manufacturing organization (CDMO) dedicated to advancing viral vectors, vaccines, biologics, and advanced therapies from early development through commercial manufacturing.
Operating across the United States and Europe, the Company combines world-class expertise in viral vectors, AAV, oncolytic viruses and vaccines, with six decades of biologics manufacturing excellence and long-standing experience supporting biotechnology innovators, pharmaceutical companies, academic institutions, and U.S. Government programs. ABL Ascend's comprehensive capabilities today stretch across the entire CDMO value chain, from process and analytical development, to clinical and commercial GMP manufacturing and aseptic fill finish.
Learn more at https://ablinc.com and https://www.ascend-adv.com.
Media Contact: business@ascend-adv.com
SOURCE: EW Healthcare Partners
EW Healthcare Partners
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Europe SPAC Summit 2026 to Convene Leading SPAC Sponsors, Investors, and European Growth Companies in Zurich on December 1019.8.2026 15:00:00 CEST | Press release
One-Day, Invitation-Only Summit Maps the Path from European Innovation to U.S. Capital Markets NEW YORK, NY AND ZURICH, SWITZERLAND / ACCESS Newswire / August 19, 2026 / As a landmark year for European companies in the U.S. public markets continues to build momentum, the Europe SPAC Summit will convene the dealmakers driving the region's de-SPAC renaissance, turning its focus to deal flow, capital formation, and every stage of the path from European innovation to a thriving U.S. listing. The invitation-only Summit takes place on Thursday, December 10, 2026, at The Dolder Grand in Zurich, Switzerland, co-hosted by AUM Advisors and MBP Global. The Summit features a keynote session with Kyivstar, Ukraine's largest mobile operator, whose successful Nasdaq listing through a merger with a SPAC sponsored by Cohen Circle, the investment platform founded by fintech pioneer Betsy Cohen, demonstrates that this approach can create real value for Europe's growth companies. The program also includes
LiberNovo Previews Support Week 2026, Putting Better Ergonomic Support Within Reach18.8.2026 10:00:00 CEST | Press release
Support Week starts August 25. We've got your back. HONG KONG, HK / ACCESS Newswire / August 18, 2026 / One size does not fit all. Yet most ergonomic chairs are still built around a standard frame, leaving taller, broader, and heavier users adapting to the chair instead of the chair adapting to them. LiberNovo is addressing that gap with the Maxis Series, the lead range for LiberNovo Support Week 2026, opening August 25 across the European Union and United Kingdom. Built for Bigger Builds Maxis was engineered at full scale, not adapted from a standard chair platform. A 52 cm seat depth provides greater thigh support, while a wider seat cushion gives users more room to shift naturally. Its reinforced frame supports up to 181 kg. Maxis also features a five-stage recline control system from 105° to 160°, supported by a Segmented Support System using progressive springs. This provides controlled, consistent support throughout the recline range, even under heavier loads. Three configuration
U.S. Polo Assn. Takes No. 1 Spot for All Sports Brands and Climbs to No. 22 Overall on License Global's 2026 'Top Global Licensors' Ranking13.8.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / August 13, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), was named the highest-ranking sports brand on License Global's annual Top Global Licensor list for the second consecutive year, surpassing the NFL Players Association, PGA Tour, and Formula 1. Marking another milestone, U.S. Polo Assn. climbs to No. 22 overall on the global licensor list spanning the entertainment, fashion, lifestyle, and sports industries. This achievement reflects the continued expansion of the multi-billion-dollar brand globally as it delivered a record year on all fronts with $2.7B in retail sales in 2025. U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), ranked the No. 1 Sports Licensor on License Global's annual Top Global Licensor list. This achievement reflects the continued expansion of the multi-billion-dollar sport brand globally as it delivered a record year on all fronts
GoodData.AI Cuts BI Migration From 18 Months to Weeks for DACH Enterprises, Opening the Fastest Route to Production AI12.8.2026 16:20:00 CEST | Press release
With around 80 percent of migration functions automated, enterprises skip the multi-year consulting engagement that has kept them on aging BI platforms. SAN FRANCISCO, CA / ACCESS Newswire / August 12, 2026 / GoodData.AI today announced its AI-driven BI migration offering for enterprises across Germany, Austria, and Switzerland, delivered with German-language support and a regional team. Migration agents are able to move organizations off Tableau, Power BI, Qlik, Looker, MicroStrategy, and any other BI platform in days to weeks instead of the 12 to 18 months that a manual rebuild takes. Up to 80 percent of the migration work is automated, which cuts the cost along with the timeline, and GoodData engineers review every change before the customer approves it. It follows GoodData.AI's expansion in the region earlier this year and its work with DATEV, one of Germany's most recognized enterprise software companies. "Every migration conversation in Germany starts with the same question: will
Karbon-X and Core Energy Sign Letter of Intent to Explore Commercial EV Charging Infrastructure in South America12.8.2026 15:00:00 CEST | Press release
Collaboration provides Karbon-X with an opportunity to apply its project development and carbon market capabilities to commercial transportation infrastructure in the Southern Cone. CALGARY, AB / ACCESS Newswire / August 12, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has signed a non-binding Letter of Intent ("LOI") with Core Energy ("Core Energy"), to explore a potential commercial electric vehicle ("EV") fast-charging infrastructure project in South America. The proposed collaboration is intended to bring together Core Energy's local project development capabilities and Karbon-X's experience evaluating and developing climate projects and carbon market opportunities. During the initial exploratory phase, the companies expect to jointly assess the project's preliminary technical and commercial considerations and prepare a Concept Note outlining the proposed infrastructure model and its pot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom